Date: 2017-03-17
Type of information: Grant
Company: Emergent Biosolutions (USA - MD)
Investors: Biomedical Advanced Research and Development Authority (BARDA) (USA)
Amount: $100 million
Funding type: grant
Planned used:
Others:
- • On March 17, 2017, Emergent BioSolutions announced that it has signed a two-year contract with the Biomedical Advanced Research and Development Authority (BARDA), a division within the Office of the Assistant Secretary of Preparedness and Response, valued at $100 million for the delivery of BioThrax® (Anthrax Vaccine Adsorbed) to the Strategic National Stockpile (SNS). This contract satisfies BARDA's notice of intent to sole source BioThrax that was issued on December 8, 2016 and is separate from and in addition to the company’s $911 million BioThrax procurement contract with the Centers for Disease Control and Prevention (CDC). BioThrax pricing under this BARDA procurement contract is the same as BioThrax pricing under the CDC follow-on contract.
- Simultaneously with the execution of this procurement contract, the company signed a modification to its September 30, 2016 contract with BARDA for the development and procurement of NuThrax™ (anthrax vaccine adsorbed with CPG 7909 adjuvant), the company’s next generation anthrax vaccine candidate. The modification increases the number of doses of NuThrax to be delivered under the base period from two million to three million doses with a commensurate reduction in dose price for the initial deliveries. The modification also reduces the purchase price for doses to be procured during the option period by $100 million thereby reducing the total contract value to be up to $1.5 billion, from the previously disclosed $1.6 billion.
- Contract HHSO100201700007C for the procurement of BioThrax and contract HHSO100201600030C for the advanced development and delivery of NuThrax have both been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, at the U.S. Department of Health and Human Services.
Therapeutic area: Infectious diseases
Is general: Yes
